Literature DB >> 26874795

The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer.

Juha P Väyrynen1,2, Tiina Kantola1,2, Sara A Väyrynen1,2, Kai Klintrup3,4, Risto Bloigu5, Toni Karhu6, Jyrki Mäkelä3,4, Karl-Heinz Herzig6,7, Tuomo J Karttunen1,2, Anne Tuomisto1,2, Markus J Mäkinen1,2.   

Abstract

Increased inflammatory cell infiltration correlates to improved survival in colorectal cancer (CRC). Development and progression of CRC is associated with alterations in serum cytokine levels but their significance is not well defined. In this study, we investigated the relationships between the serum levels of 13 cytokines and the densities of eight types of tumor infiltrating inflammatory cells and their impact on disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) in a prospectively recruited group of 147 CRC patients. There were strong positive correlations between the serum concentrations of different cytokines, as well as between the different types of tumor infiltrating immune cells, whereas the associations between serum cytokines and tumor infiltrating immune cells were generally weak. High serum IL-12 levels associated with increased densities of peritumoral CD8(+) T cells, intraepithelial CD3(+) T cells and intratumoral neutrophils, while high serum CCL4 levels associated with increased densities of peritumoral CD68(+) cells. In multivariate survival models, increased infiltration of intraepithelial CD3(+) T cells and increased serum CCL4 associated with improved DFS, whereas higher intratumoral CD83(+) dendritic cell density and increased serum interferon gamma levels associated with improved CSS and OS. Also high density of peritumoral CD3(+) T cells associated with improved CSS. In conclusion, serum cytokines and tumor infiltrating immune cells in CRC represent entities with high intragroup correlations but relatively weak intergroup correlations. The results suggest that tumor infiltrating CD3(+) T cells, CD83(+) dendritic cells, serum CCL4 and serum interferon gamma represent relevant markers of disease outcome.
© 2016 UICC.

Entities:  

Keywords:  T cell; colorectal cancer; cytokine; dendritic cell; serum

Mesh:

Substances:

Year:  2016        PMID: 26874795     DOI: 10.1002/ijc.30040

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Integrative analysis identifies DNMTs against immune-infiltrating neutrophils and dendritic cells in colorectal cancer.

Authors:  Qili Shi; Libing Shen; Jun Gan; Lirong He; Jing Lin; Shiyu Guo; Zi Xiong; Jie Lin; Shun Zhang
Journal:  Epigenetics       Date:  2019-03-16       Impact factor: 4.528

2.  Role of microRNA-141 in colorectal cancer with lymph node metastasis.

Authors:  Li Feng; Hongqing Ma; Liang Chang; Xinliang Zhou; Na Wang; Lianmei Zhao; Jing Zuo; Yudong Wang; Jing Han; Guiying Wang
Journal:  Exp Ther Med       Date:  2016-09-27       Impact factor: 2.447

3.  Serum cytokine profile as a potential prognostic tool in colorectal cancer patients - one center study.

Authors:  Paulina Czajka-Francuz; Tomasz Francuz; Sylwia Cisoń-Jurek; Aleksander Czajka; Marcin Fajkis; Bożena Szymczak; Maciej Kozaczka; Krzysztof Piotr Malinowski; Wojciech Zasada; Jerzy Wojnar; Jerzy Chudek
Journal:  Rep Pract Oncol Radiother       Date:  2020-08-21

4.  Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Authors:  Mireia Uribe-Herranz; Kyle Bittinger; Stavros Rafail; Sonia Guedan; Stefano Pierini; Ceylan Tanes; Alex Ganetsky; Mark A Morgan; Saar Gill; Janos L Tanyi; Frederic D Bushman; Carl H June; Andrea Facciabene
Journal:  JCI Insight       Date:  2018-02-22

5.  Decreased preoperative serum 25-Hydroxyvitamin D levels in colorectal cancer are associated with systemic inflammation and serrated morphology.

Authors:  Juha P Väyrynen; Shivaprakash J Mutt; Karl-Heinz Herzig; Sara A Väyrynen; Tiina Kantola; Toni Karhu; Tuomo J Karttunen; Kai Klintrup; Jyrki Mäkelä; Markus J Mäkinen; Anne Tuomisto
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

6.  Obesity Does Not Exacerbate the Protumorigenic Systemic Environment in Sarcoma Subjects.

Authors:  Claire M Buchta; Shannon K Boi; Benjamin J Miller; Mohammed M Milhem; Lyse A Norian
Journal:  Immunohorizons       Date:  2017-06-05

7.  The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment.

Authors:  Juha P Väyrynen; Koichiro Haruki; Mai Chan Lau; Sara A Väyrynen; Jeffrey A Meyerhardt; Marios Giannakis; Shuji Ogino; Jonathan A Nowak; Rong Zhong; Andressa Dias Costa; Jennifer Borowsky; Melissa Zhao; Kenji Fujiyoshi; Kota Arima; Tyler S Twombly; Junko Kishikawa; Simeng Gu; Saina Aminmozaffari; Shanshan Shi; Yoshifumi Baba; Naohiko Akimoto; Tomotaka Ugai; Annacarolina Da Silva; Jennifer L Guerriero; Mingyang Song; Kana Wu; Andrew T Chan; Reiko Nishihara; Charles S Fuchs
Journal:  Cancer Immunol Res       Date:  2020-10-06       Impact factor: 12.020

8.  Clinical impact and network of determinants of tumour necrosis in colorectal cancer.

Authors:  Sara A Väyrynen; Juha P Väyrynen; Kai Klintrup; Jyrki Mäkelä; Tuomo J Karttunen; Anne Tuomisto; Markus J Mäkinen
Journal:  Br J Cancer       Date:  2016-05-19       Impact factor: 7.640

9.  Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer.

Authors:  Florian Posch; Karina Silina; Sebastian Leibl; Axel Mündlein; Holger Moch; Alexander Siebenhüner; Panagiotis Samaras; Jakob Riedl; Michael Stotz; Joanna Szkandera; Herbert Stöger; Martin Pichler; Roger Stupp; Maries van den Broek; Peter Schraml; Armin Gerger; Ulf Petrausch; Thomas Winder
Journal:  Oncoimmunology       Date:  2017-12-18       Impact factor: 8.110

10.  Preoperative anemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival.

Authors:  Juha P Väyrynen; Anne Tuomisto; Sara A Väyrynen; Kai Klintrup; Toni Karhu; Jyrki Mäkelä; Karl-Heinz Herzig; Tuomo J Karttunen; Markus J Mäkinen
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.